1. Home
  2. PRG vs VERA Comparison

PRG vs VERA Comparison

Compare PRG & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PROG Holdings Inc.

PRG

PROG Holdings Inc.

HOLD

Current Price

$29.76

Market Cap

1.4B

ML Signal

HOLD

Logo Vera Therapeutics Inc.

VERA

Vera Therapeutics Inc.

HOLD

Current Price

$46.84

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRG
VERA
Founded
2020
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.5B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
PRG
VERA
Price
$29.76
$46.84
Analyst Decision
Buy
Strong Buy
Analyst Count
7
11
Target Price
$37.50
$76.60
AVG Volume (30 Days)
605.8K
1.5M
Earning Date
02-18-2026
11-05-2025
Dividend Yield
1.77%
N/A
EPS Growth
10.59
N/A
EPS
3.96
N/A
Revenue
$2,507,179,000.00
N/A
Revenue This Year
$1.24
N/A
Revenue Next Year
$7.02
N/A
P/E Ratio
$7.42
N/A
Revenue Growth
3.71
N/A
52 Week Low
$23.50
$18.53
52 Week High
$44.43
$56.05

Technical Indicators

Market Signals
Indicator
PRG
VERA
Relative Strength Index (RSI) 49.28 53.97
Support Level $30.10 $47.22
Resistance Level $30.76 $56.05
Average True Range (ATR) 0.73 2.35
MACD -0.11 -1.00
Stochastic Oscillator 33.56 9.63

Price Performance

Historical Comparison
PRG
VERA

About PRG PROG Holdings Inc.

PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.

About VERA Vera Therapeutics Inc.

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

Share on Social Networks: